폴리글리콜산 시장 : 원료별, 형태별, 순도 등급별, 용도별, 최종 이용 산업별, 유통 채널별 시장 예측(2026-2032년)

The Polyglycolic Acid Market is projected to grow by USD 12.75 billion at a CAGR of 9.97% by 2032.

Polyglycolic acid, commonly abbreviated as PGA, is a high-performance biodegradable aliphatic polyester valued for high tensile strength, rapid hydrolytic degradation, and strong gas-barrier performance. Its established use in absorbable surgical sutures and growing relevance in biomedical devices, controlled-release systems, high-barrier packaging, and degradable industrial components make it a strategically important material across healthcare, energy, and sustainability-linked industries.

Market momentum is supported by verified application fundamentals rather than speculative demand alone. PGA degrades through hydrolysis into glycolic acid, a metabolizable compound, and the material is widely evaluated under recognized biocompatibility, sterilization, and sterile barrier packaging frameworks, including ISO 10993 and ISO 11607 where applicable. As buyers prioritize performance, regulatory confidence, supply security, and end-of-life outcomes, PGA is positioned as a premium specialty polymer within the broader biodegradable polymers landscape.

Transformative Shifts in the Polyglycolic Acid Landscape

The polyglycolic acid landscape is shifting from a niche medical-materials base toward a broader platform for sustainable and high-performance applications. Producers are improving polymerization, purification, and melt-processing routes to address PGA's moisture sensitivity, thermal-processing constraints, and brittleness, while compounders are blending PGA with other biopolymers to balance degradation rate, flexibility, barrier performance, and cost-to-performance requirements.

A second transformation is occurring through demand diversification. In healthcare, absorbable implants, sutures, meshes, and tissue engineering scaffolds continue to benefit from PGA's proven resorption profile. In industrial applications, high-barrier films and degradable downhole tools are gaining attention because PGA combines strength with controlled hydrolysis. This convergence of clinical reliability, sustainability pressure, and application engineering is reshaping competitive strategy for polyglycolic acid materials.

Cumulative Impact of Artificial Intelligence on PGA

Artificial intelligence is beginning to create cumulative value across PGA discovery, manufacturing, quality assurance, and commercialization. AI-enabled molecular modeling can help screen copolymer ratios, stabilizers, additives, and processing windows before costly pilot trials, while machine learning models can support prediction of hydrolysis behavior, tensile retention, crystallinity changes, and sterilization impact using validated experimental datasets.

In operations, AI-driven process analytics can improve reaction control, viscosity consistency, impurity monitoring, defect detection, and batch traceability. For regulated medical applications, AI does not replace validation, good manufacturing practice, or biocompatibility testing; however, it can shorten learning cycles, strengthen documentation workflows, support design history files, and improve risk management when integrated with ISO 13485, FDA quality system expectations, and robust internal data governance.

Key Regional Insights for Polyglycolic Acid

Asia-Pacific is a major growth arena for polyglycolic acid due to strong chemical manufacturing capacity, expanding medical device production, and demand for advanced biodegradable polymers in China, India, Japan, South Korea, and Australia. The region benefits from integrated polymer processing ecosystems, policy support for healthcare manufacturing, and rising interest in lower-impact packaging materials. North America remains highly influential because of its regulated healthcare ecosystem, established absorbable suture demand, materials research capabilities, and innovation in degradable shale gas and specialty industrial tools. Latin America is more opportunity-led, with Brazil and Mexico supporting demand through healthcare modernization, medical device assembly, and packaging sustainability initiatives.

Europe advances PGA through medical technology, circular economy policy, and research into lower-impact polymers, with Germany, France, Italy, Spain, and the United Kingdom supporting application development under rigorous regulatory and quality expectations. The Middle East is relevant through energy-sector use cases, particularly degradable downhole components and specialty chemical investment aligned with oilfield efficiency. Africa represents an emerging demand base tied to healthcare access, infrastructure investment, and gradual adoption of higher-performance medical materials, with long-term potential supported by public health procurement and regional industrial development.

Key Economic Group Insights for PGA

ASEAN demand is shaped by medical manufacturing hubs, export-oriented polymer processing, and rising healthcare expenditure, making the group relevant for downstream PGA conversion and specialty packaging development. The GCC is closely linked to energy applications and specialty chemical investment, where degradable materials can support well-completion efficiency, reduced intervention requirements, and operational simplification. The European Union provides one of the strongest regulatory and sustainability signals, encouraging validated biocompatible and lower-waste material solutions while requiring credible evidence on safety, performance, and environmental claims.

BRICS economies represent scale, with China and India anchoring manufacturing and demand development while Brazil, Russia, and South Africa add regional healthcare, energy, and industrial potential. G7 markets remain central for innovation, intellectual property, clinical validation, advanced manufacturing, and high-value medical device adoption. NATO countries add a resilience dimension, as secure supply chains for medical materials, specialty polymers, sterilized devices, and critical healthcare inputs are increasingly viewed as strategic industrial capabilities.

Key Country Insights for Polyglycolic Acid

The United States leads in high-value medical devices, absorbable wound-closure products, advanced biomaterials research, and degradable oilfield applications, while Canada contributes through healthcare quality standards, academic materials research, and regulated medical procurement. Mexico benefits from nearshoring, medical device assembly, and packaging conversion, and Brazil anchors Latin American demand through its large healthcare system and industrial base. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical demand, polymer expertise, sterilization knowledge, and regulatory rigor, while Russia's relevance is tied to energy applications, domestic industrial substitution, and demand for specialty materials in resource-sector operations.

China is a pivotal country for PGA due to chemical production capacity, scale manufacturing, polymer processing capabilities, and demand for biodegradable materials. India offers momentum through healthcare expansion, pharmaceutical and medical device manufacturing, and cost-competitive industrial development. Japan and South Korea contribute precision polymer processing, medical technology, quality-focused manufacturing, and electronics-adjacent materials expertise, while Australia supports adoption through healthcare quality systems, research capability, and demand for specialized medical and industrial products.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize application-specific positioning rather than treating PGA as a commodity biodegradable polymer. Medical-grade PGA requires validated biocompatibility, sterilization compatibility, traceability, mechanical retention, and controlled degradation profiles, while packaging and industrial applications require proof of processability, barrier performance, moisture sensitivity management, mechanical stability, and cost-to-performance advantage.

Executives should invest in copolymer and blend development, secure glycolide and raw-material supply, and build partnerships with device makers, film converters, contract manufacturers, research institutions, and energy-service providers. Leaders should also strengthen lifecycle documentation, regulatory intelligence, supplier qualification, and AI-enabled quality analytics to reduce qualification time and improve customer confidence in safety-critical and performance-critical applications.

Research Methodology

The research methodology integrates secondary research, regulatory review, patent and publication screening, application-level benchmarking, and technical analysis across medical, industrial, and packaging uses of polyglycolic acid. Verified sources considered include standards bodies, regulatory databases, peer-reviewed polymer science literature, public patent records, trade data indicators, public healthcare documentation, energy-sector technical references, and recognized material safety and quality frameworks.

Market interpretation is built through triangulation, comparing material properties, end-use adoption signals, regional manufacturing capabilities, processing constraints, and regulatory requirements. Qualitative insights are validated against known PGA characteristics, including hydrolytic degradation, high strength, high crystallinity, and high gas-barrier performance, while avoiding unsupported market-size, market-share, or forecasting claims where reliable public evidence is not available.

Conclusion

Polyglycolic acid is moving into a more strategic phase as industries seek materials that combine verified performance with controlled degradation. Its established clinical use gives it credibility, while emerging applications in high-barrier packaging, industrial tools, controlled-release systems, and advanced biomedical engineering expand its relevance across multiple regulated and performance-driven sectors.

Future competitiveness will depend on quality consistency, processing innovation, regional supply security, regulatory readiness, and evidence-based sustainability claims. Organizations that align PGA development with application-specific economics, validated performance data, and evolving healthcare, energy, and packaging requirements will be best positioned in this premium biodegradable polymer landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Polyglycolic Acid Market, by Raw Material Source

• 7.1. Corn-based PLA
• 7.2. Sugarcane-based PLA
• 7.3. Cassava-based PLA
• 7.4. Beet sugar-based PLA

8. Polyglycolic Acid Market, by Form

• 8.1. Fibers
  • 8.1.1. Woven
  • 8.1.2. Non-woven
• 8.2. Films
  • 8.2.1. Cast
  • 8.2.2. Blown
• 8.3. Sheet
• 8.4. Granules
• 8.5. Powders

9. Polyglycolic Acid Market, by Purity Grade

• 9.1. Industrial Grade
• 9.2. Medical Grade

10. Polyglycolic Acid Market, by Application

• 10.1. Drug Delivery
• 10.2. Packaging
  • 10.2.1. Food Packaging
  • 10.2.2. Industrial Packaging
  • 10.2.3. Pharmaceutical Packaging
• 10.3. Surgical Sutures
• 10.4. Tissue Engineering
  • 10.4.1. Cardiac Repair
  • 10.4.2. Orthopedic Applications

11. Polyglycolic Acid Market, by End Use Industry

• 11.1. Automotive
• 11.2. Medical
• 11.3. Packaging
• 11.4. Textile

12. Polyglycolic Acid Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Polyglycolic Acid Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Polyglycolic Acid Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Polyglycolic Acid Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aarti Industries Limited
• 17.2. Advanced Medical Solutions Group PLC
• 17.3. BMG Incorporated
• 17.4. Chemical Crunch Pvt Ltd
• 17.5. Corbion NV
• 17.6. Daicel Corporation
• 17.7. DuPont de Nemours Inc
• 17.8. Eddy Health Care
• 17.9. Emirates Biotech LLC
• 17.10. Ethicon Inc
• 17.11. Evonik Industries AG
• 17.12. Foster Group Inc
• 17.13. Hu-Friedy Mfg Co LLC
• 17.14. Huizhou Foryou Medical Devices Co Ltd
• 17.15. Kureha Corporation
• 17.16. Lotus Surgicals Private Limited
• 17.17. Merck KGaA
• 17.18. Meta Biomed Co Ltd
• 17.19. Orion Sutures India Pvt Ltd
• 17.20. Samyang Holdings Biopharma Group
• 17.21. Shandong Haidike Medical Products Co Ltd
• 17.22. Shanghai Pujing Chemical Co Ltd
• 17.23. Shenzhen Polymtek Biomaterial Co Ltd
• 17.24. SK Chemicals Co Ltd
• 17.25. Sumitomo Chemical Co Ltd
• 17.26. Teleflex Incorporated
• 17.27. Thurs Organics Private Limited
• 17.28. Unisur Lifecare Pvt Ltd